# Pairidex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pairidex

- Industry: Biotechnology
- Headquarters: St. Louis, US
- Website: www.pairidex.com/
- Total disclosed funding: $4.9M
- Latest round: Seed (Feb 23, 2026)
- Investors on record: 2

## About

Based in Missouri, United States and founded in 2023, Pairidex Inc., founded by Andrew Young (Founder & Chief Scientific Officer), provides personalized molecular diagnostic testing and measurable residual disease (MRD) monitoring solutions for blood cancers through its FusionMRD™ platform for the healthcare and life sciences industry. The company is led by Paul Kortschak (Chief Executive Officer). In July 2026, Pairidex raised USD 4.89 million in seed funding from BioGenerator. Other unspecified investors also participated in the round. The company generates revenue by providing FusionMRD™ blood cancer testing services and personalized molecular diagnostic solutions for disease monitoring. The company plans to use the July 2026 funding to accelerate the commercial launch of its FusionMRD blood cancer testing platform, expand clinical studies and laboratory operations, and advance development of its personalized molecular diagnostics platform

## Funding rounds

- Seed, Feb 23, 2026, $4.9M — BioGenerator, Missouri Technology Corporation

## Investors

- BioGenerator (https://capitalatlas.ai/funds/biogenerator) — Seed
- Missouri Technology Corporation — Seed